Company Filing History:
3 out of 547 
1 out of 3,539 
1 out of 4,550 
Years Active: 2014-2019
Title: Kelin Li: Innovator in Antiviral Compounds
Introduction
Kelin Li is a notable inventor based in Lawrence, KS (US), recognized for his contributions to the field of antiviral agents. With a total of 3 patents, his work focuses on developing compounds that target viral infections and cancers.
Latest Patents
Kelin Li's latest patents include significant advancements in the realm of heterocyclic compounds. One of his inventions discloses compounds of formula (I), formula (II), and formula (III), which are designed as antiviral agents for the treatment of viral infections, such as hepatitis C. These compounds are also considered for use in treating or preventing various cancers. Another patent details HCV helicase inhibitors, specifically thioflavine S and primuline derivatives, which inhibit hepatitis C virus helicase and protease activity. These compounds disrupt the life cycle of the hepatitis C virus, proving useful as antiviral agents. Additionally, this invention encompasses pharmaceutical compositions that utilize these compounds for treating HCV infections.
Career Highlights
Kelin Li has worked with esteemed institutions, including the University of Kansas Medical Center Research Institute and the National Institutes of Health, a component of the US Department of Health & Human Services. His research has significantly contributed to the understanding and treatment of viral infections.
Collaborations
Throughout his career, Kelin Li has collaborated with notable colleagues, including Kevin Frankowski and Frank John Schoenen. Their combined efforts have furthered advancements in antiviral research.
Conclusion
Kelin Li's innovative work in developing antiviral compounds showcases his dedication to addressing critical health challenges. His patents reflect a commitment to improving treatment options for viral infections and cancers.